ArticleEMBO molecular medicine2016
Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.
Article in EMBO molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.Stem cell reviews and reports · 2024Article
- Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy.Cells · 2024Review
- Assessing and enhancing migration of human myogenic progenitors using directed iPS cell differentiation and advanced tissue modelling.EMBO molecular medicine · 2022Article
- Imaging in experimental models of diabetes.Acta diabetologica · 2022Review
- Extracellular vesicle-derived miRNAs improve stem cell-based therapeutic approaches in muscle wasting conditions.Frontiers in immunology · 2022Article
- Human muscle production in vitro from pluripotent stem cells: Basic and clinical applications.Seminars in cell & developmental biology · 2021Review
- Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.Stem cells translational medicine · 2021Article
- Merosin deficient congenital muscular dystrophy type 1A: An international workshop on the road to therapy 15-17 November 2019, Maastricht, the Netherlands.Neuromuscular disorders : NMD · 2021Article
- Systemic cell therapy for muscular dystrophies : The ultimate transplantable muscle progenitor cell and current challenges for clinical efficacy.Stem cell reviews and reports · 2021Review
- Cellular dynamics of myogenic cell migration: molecular mechanisms and implications for skeletal muscle cell therapies.EMBO molecular medicine · 2020Review
- Therapeutic developments for Duchenne muscular dystrophy.Nature reviews. Neurology · 2019Review
Corrections and comments
- Erratum for
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.